Two Syn­cona-backed play­ers join forces to take on reti­nal gene ther­a­pies

With am­bi­tions to build an eye gene-ther­a­py pow­er­house, UK-based Gy­ro­scope Ther­a­peu­tics is swal­low­ing US-based de­vice mak­er Or­bit Bio­med­ical, which is fo­cused on sub-reti­nal sur­gi­cal de­liv­ery tech­nol­o­gy.

The com­bi­na­tion of the two Syn­cona-backed play­ers — which will op­er­ate un­der the Gy­ro­scope name — will be led by for­mer Genen­tech ex­ec­u­tive Khurem Fa­rooq, who was re­spon­si­ble for man­ag­ing the com­mer­cial ac­tiv­i­ties of Lu­cen­tis and in­volved in the pre-launch work for lam­pal­izum­ab at the Roche com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER